Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458613 | 0.97 | P2RX7 (0.63) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483795 | 0.93 | P2RX7 (0.60) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2456611 | 0.91 | P2RX7 (0.65) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483761 | 0.89 | P2RX7 (0.76) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9490535 | 0.89 | P2RX7 (0.51) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484514 | 0.86 | P2RX7 (0.65) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2456866 | 0.86 | P2RX7 (0.53) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484296 | 0.86 | P2RX7 (0.75) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483261 | 0.85 | P2RX7 (0.54) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2456056 | 0.85 | P2RX7 (0.51) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5244895-A | 5-Isoquinolinesulfonamides with N substituents containing benzyl and heterocyclic groups | Hidaka, Hiroyoshi (JP) | 1993-09-14 | — | — | US | claimed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| EP-0513691-B1 | Anti-ulcer agent | HIDAKA HIROYOSHI (JP) | 1996-07-31 | — | — | EP | disclosed |
| US-5244895-A | 5-Isoquinolinesulfonamides with N substituents containing benzyl and heterocyclic groups | Hidaka, Hiroyoshi (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0513691-A1 | Anti-ulcer agent | Hidaka, Hiroyoshi (JP) | 1992-11-19 | — | — | EP | disclosed |
| US-5081246-A | Isoquinolino sulfonamino derivatives | Hidaka, Hiroyoshi (JP) | 1992-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | P2RX7 2569/4885ALDH1A1 3179/4885SMN1; SMN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.